{"id":"NCT02878603","sponsor":"Sanofi","briefTitle":"Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)","officialTitle":"Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-06","primaryCompletion":"2020-10-23","completion":"2020-10-23","firstPosted":"2016-08-25","resultsPosted":"2021-11-22","lastUpdate":"2022-03-28"},"enrollment":104,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Thrombotic Thrombocytopenic Purpura"],"interventions":[{"type":"BIOLOGICAL","name":"Caplacizumab","otherNames":[]},{"type":"OTHER","name":"Standard of Care","otherNames":[]}],"arms":[{"label":"caplacizumab","type":"EXPERIMENTAL"}],"summary":"The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).","primaryOutcome":{"measure":"Percentage of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Related Events","timeFrame":"From Baseline up to 36 months","effectByArm":[{"arm":"Standard of Care (SoC) (Treated in Study C301)","deltaMin":37.9,"sd":null},{"arm":"Caplacizumab (Treated in Study C301)","deltaMin":8.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["United States","Austria","Belgium","Canada","Czechia","France","Hungary","Israel","Italy","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["36138517"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":29},"commonTop":["Headache","Adamts13 Activity Decreased","Dizziness","Nasopharyngitis","Diarrhoea"]}}